Skip to main content
TipRanks
Go Ultimate75% OFF

Repligen (RGEN) AI Stock Analysis

1,003 Followers
RGEN

Repligen

(NASDAQ:RGEN)

Select Model
Rating:63Neutral
Price Target:$185.00â–²(14.07% Upside)
Action:reiterated
Date:11/07/26

RGEN scores mid-range primarily due to strong cash flow and a solid balance sheet supporting flexibility, reinforced by upbeat guidance and positive management sentiment pointing to accelerating growth. These positives are tempered by currently weak GAAP profitability (negative TTM net income), weak-to-neutral near-term technical momentum, and an unfavorable valuation signal from the deeply negative P/E with no dividend yield provided.

Positive Factors
Recurring consumables and services demandStrong consumable and service growth supports a recurring revenue base because these products and support contracts remain embedded in customer workflows. Expanding service coverage can deepen relationships, improve revenue visibility, and create durable follow-on opportunities as bioprocessing activity grows.
Negative Factors
Negative GAAP profitability and lower marginsNegative TTM net income indicates that operating performance has not yet translated into consistent bottom-line profitability. Margins below prior peaks also reduce earnings resilience, potentially limiting internally funded investment and making future results more sensitive to mix, costs, and execution.

Repligen (RGEN) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%30%RGEN+5.07%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$10.37B
Dividend Yield
―
Average Volume (3M)
1.19M
Price to Earnings (P/E)
-770.4
Beta (1Y)
1.38
Revenue Growth
13.80%
EPS Growth
-811.00%
Country
US
Employees
2,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

Repligen Business Overview & Revenue Model

Company Description

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe,...

How the Company Makes Money

Repligen makes money primarily by selling bioprocessing products to biopharmaceutical and life sciences customers that manufacture biologic drugs. Its revenue model is largely product-based and is typically driven by: (1) recurring sales of consumabl...

Repligen Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:-9.99%|Next Earnings Date:Feb 24, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Repligen reported record revenue, double-digit organic growth, operating margin expansion, higher full-year guidance, strong demand in chromatography, proteins, analytics, China, services, and capital equipment orders, and encouraging early progress integrating BioLife. The company acknowledged meaningful challenges, including an 11% filtration decline, delayed equipment revenue conversion, a 30-basis-point gross margin decline, customer decision delays, and on-shoring projects running 9 to 12 months behind expectations, but management expressed confidence in the 2027 outlook and continued market-share and growth opportunities.

Positive Updates

Record Revenue and Strong Organic Growth
Third-quarter revenue reached a record $209 million, surpassing the prior peak from the second quarter of 2022. Reported revenue growth was 11%, while organic growth was 12.5%, despite lapping a very strong prior-year quarter.

Negative Updates

Filtration Revenue Declined 11%
Filtration revenue declined 11% in the quarter, including a 2-point headwind from the PolyMem divestment and foreign currency. The decline also reflected the previously disclosed ACF and gene therapy program headwinds, two customer headwinds on ATF, and system deliveries requested by customers for 2027. Full-year filtration revenue is now expected to be flat to slightly down, including the inorganic impact of the PolyMem sale.

Company Guidance

For full year 2026, Repligen guides to $844 million to $852 million of revenue, or $848 million at the midpoint, representing 14.5% to 15.5% reported growth and 12% to 13% organic growth, including approximately $24 million from BioLife, an approximately 1-point headwind from the sale of PolyMem operations, and neutral foreign currency; franchise guidance is filtration flat to slightly down, chromatography greater than 30%, proteins mid-teens, and analytics more than 30% growth. The company expects 110- to 160-basis-points of gross margin expansion, adjusted operating income of $135 to $139 million, adjusted operating margin of 16% to 16.3%, adjusted other income of $18 million, an adjusted tax rate of approximately 22%, adjusted fully diluted earnings per share of $2.05 to $2.09, and CapEx of approximately 3% to 4% of 2026 revenue; fourth quarter organic growth is expected to be in the range of the updated full year outlook, fourth quarter gross margin within the full year guidance, and operating expenses up low-double-digits million sequentially. For 2027, assuming the market is growing high-single-digits and absent a material change in foreign exchange rates, reported top-line growth is positioned at least 25%, revenue is expected to exceed $1 billion, and BioLife is expected to deliver at least $0.05 of Year 1 accretion, while the company continues to target outpacing market growth by more than 500 basis points; the 2027 framework is not a formal guidance.

Repligen Financial Statement Overview

Summary

Financials are supported by a solid balance sheet (72) with moderate leverage and strong cash generation (74) with healthy free cash flow, but overall performance is held back by mixed earnings quality: revenue has stabilized and EBITDA remains positive, yet TTM net income is negative and margins are below 2021–2022 peak levels (income statement score 58).

Income Statement

58Neutral

Balance Sheet

72Positive

Cash Flow

74Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue805.61M738.26M634.44M632.36M801.54M670.53M
Gross Profit411.27M347.62M274.64M278.44M455.71M391.25M
EBITDA125.87M182.51M80.26M145.32M277.31M203.27M
Net Income-11.80M48.89M-25.51M35.60M185.96M128.29M
Balance Sheet
Total Assets2.93B2.95B2.83B2.83B2.53B2.36B
Cash, Cash Equivalents and Short-Term Investments862.98M767.63M757.36M751.32M623.76M603.81M
Total Debt692.24M689.95M686.25M711.80M422.96M366.05M
Total Liabilities834.67M843.57M856.95M866.34M620.90M608.29M
Stockholders Equity2.09B2.11B1.97B1.96B1.91B1.75B
Cash Flow
Free Cash Flow106.22M93.90M142.49M74.93M38.74M51.93M
Operating Cash Flow129.86M117.42M175.39M113.92M172.08M119.02M
Investing Cash Flow-150.83M-298.47M-86.38M-123.28M-233.24M-221.17M
Financing Cash Flow3.06M-15.21M-82.90M248.96M-13.34M961.00K

Repligen Technical Analysis

Technical Analysis SentimentNegative
Last Price162.18

Price Trends

50DMA176.92Negative
100DMA166.49Negative
200DMA145.39Positive

Market Momentum

MACD-3.29Positive
RSI39.65Neutral
STOCH8.78Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGEN, the sentiment is Negative. The current price of 162.18 is below the 20-day moving average (MA) of 174.90, below the 50-day MA of 176.92, and above the 200-day MA of 145.39, indicating a neutral trend. The MACD of -3.29 indicates Positive momentum. The RSI at 39.65 is Neutral, neither overbought nor oversold. The STOCH value of 8.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RGEN.

Repligen Risk Analysis

Repligen disclosed 18 risk factors in its most recent earnings report. Repligen reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We may be unable to successfully and efficiently integrate BioLife's business into the Repligen enterprise, which could adversely affect our business, financial condition and results of operations.Q3, 2026
2.Our assumptions around the size and trajectory of the cell therapy market and BioLife's market position may prove to be incorrect, which, along with other risks and uncertainties related to the BioLife transaction, could materially and adversely affect our business and financial results.Q3, 2026
3.We may be unable to complete the pending strategic acquisition of BioLife in a timely manner or at all, and even if we are able to complete the acquisition, we may be unable to successfully integrate BioLife's business, any of which could adversely affect our business and financial condition.Q2, 2026

Repligen Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

RGEN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
WSTWST78Outperform$28.85B46.1521.08%0.22%12.60%32.05%
AVTRAVTR66Neutral$10.29B30.225.96%―0.92%―
RGENRGEN63Neutral$10.37B-770.41-0.56%―13.80%-811.00%
STVNSTVN62Neutral$4.16B27.799.07%0.41%11.99%4.96%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SOLVSOLV50Neutral$14.61B97.473.18%―-3.09%-89.72%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%RGENWSTAVTRSTVNSOLVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
RGEN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RGENRepligen162.187.104.58%
WSTWest Pharmaceutical Services, Inc.414.12156.9861.05%
AVTRAvantor15.184.1737.87%
STVNStevanato Group Spa15.25-6.01-28.28%
SOLVSolventum Corporation86.068.7511.32%

Repligen Corporate Events

Private Placements and Financing

Repligen Issues $1 Billion Convertible Notes, Restructures Debt

Positive
Nov 6, 2026

On November 6, 2026, Repligen issued $1.0 billion of 0.25% convertible senior notes due 2031 through previously announced exchange and subscription transactions. About $541.4 million of the new notes replaced $456.8 million of 1.00% notes due 2028, w...

Business Operations and StrategyStock BuybackPrivate Placements and Financing

Repligen Announces New Convertible Notes and Capital Restructuring

Positive
Oct 30, 2026

On October 30, 2026, Repligen announced privately negotiated exchange and subscription agreements through which it will issue $1.0 billion of 0.25% Convertible Senior Notes due 2031, partly swapping $456.8 million of its 1.00% Convertible Senior Note...

Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsRegulatory Filings and Compliance

Repligen Completes BioLife Acquisition to Expand Cell Therapies

Positive
Oct 6, 2026

Repligen has completed its acquisition of BioLife Solutions, a leading developer and supplier of cell processing tools and biopreservation media for the cell and gene therapy market, in a transaction that closed on October 6, 2026. The deal broadens...

Executive/Board Changes

Repligen announces long-serving director Karen Dawes’ retirement

Neutral
Sep 15, 2026

On September 10, 2026, Repligen Corporation announced that Karen A. Dawes will retire from its Board of Directors on September 30, 2026, after more than two decades of service. Her tenure spanned a period of significant transformation for the company...

M&A TransactionsRegulatory Filings and ComplianceShareholder Meetings

Repligen clears antitrust hurdle in BioLife Solutions acquisition

Positive
Sep 8, 2026

On July 21, 2026, Repligen entered into a merger agreement to acquire BioLife Solutions, Inc., with BioLife stockholders to receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife common stock. The transaction is s...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026